SCHEMBL25815904

SCHEMBL25815904

NC1CC(C(=O)O)c2c(Br)cccc21

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.39
ALDH1A1 P00352 1/20 0.36
FABP5 Q01469 1/20 0.33
HTR2C P28335 4/20 0.33
HTR2B P41595 4/20 0.33
SLC6A2 P23975 3/20 0.33
SLC6A3 Q01959 2/20 0.33
POLB P06746 1/20 0.32
CASP6 P55212 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
HDAC4 P56524 1/20 0.32
HTR2A P28223 2/20 0.32
SLC6A4 P31645 2/20 0.32
P2RX7 Q99572 1/20 0.31
PRNP P04156 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25816153 0.82 PDE5A (0.36) KDM1AALDH1A1SLC6A3POLBHDAC4
SCHEMBL5970111 0.75 SLC6A2 (0.46) KDM1AALDH1A1SLC6A2SLC6A3SLC6A4
SCHEMBL2470428 0.75 SLC6A2 (0.46) KDM1AALDH1A1SLC6A2SLC6A3SLC6A4
SCHEMBL5969949 0.75 SLC6A2 (0.46) KDM1AALDH1A1SLC6A2SLC6A3SLC6A4
SCHEMBL28226011 0.71 AADAT (0.38) ALDH1A1HTR2CHTR2BSLC6A2SLC6A3
SCHEMBL1721723 0.69 ALDH1A1 (0.47) ALDH1A1FABP5POLBCASP6CTDSP1
SCHEMBL20480557 0.67 HTR1A (0.38) ALDH1A1HTR2BPOLBCASP6CTDSP1
SCHEMBL19839756 0.67 GID4 (0.44) ALDH1A1FABP5HDAC4
SCHEMBL31110943 0.66 PARP1 (0.36) ALDH1A1HTR2BPOLBCASP6CTDSP1
SCHEMBL28226003 0.66 AADAT (0.38) ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448363-B2 Kinase inhibitors VIDYA THERAPEUTICS, INC. (US) 2025-10-21 US disclosed
CN-115867346-B Kinase inhibitors GB005股份有限公司 2025-03-14 CN disclosed
US-20230219923-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230219923-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230219923-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-07-13 US disclosed
EP-4157446-A1 KINASE INHIBITORS GB002, Inc. (US) 2023-04-05 EP disclosed
CN-115867346-A Kinase inhibitors GB005股份有限公司 2023-03-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448363-B2 Kinase inhibitors BTK, ABL1, LYN KDM1A 925/4885ALDH1A1 4364/4885FABP5 4162/4885
US-20230219923-A1 KINASE INHIBITORS BTK, ABL1, LYN KDM1A 925/4885ALDH1A1 4364/4885FABP5 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.